AP
REGN icon

AHL Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

AHL Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,044
Closed -$3.15M – 1349
2017
Q3 		$3.15M Buy
7,044
+3,900
+124% +$1.86M 0.06% 529
2017
Q2 		$1.54M Buy
+3,144
New +$1.38M 0.03% 677
2016
Q1 		– Sell
-2,762
Closed -$1.5M – 814
2015
Q4 		$1.5M Buy
2,762
+1,897
+219% +$1.03M 0.12% 318
2015
Q3 		$402K Sell
865
-4,995
-85% -$2.68M 0.06% 458
2015
Q2 		$2.99M Sell
5,860
-425
-7% -$207K 0.12% 391
2015
Q1 		$2.84M Buy
6,285
+3,479
+124% +$1.47M 0.11% 432
2014
Q4 		$1.15M Buy
+2,806
New +$1.1M 0.06% 582

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

AHL Partners's REGN Position: Q4 2017 in Review

AHL Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 7,044 shares — an estimated $3.15M sold.

AHL Partners first reported a position in REGN in Q4 2014 and held it in 7 quarters. The position peaked at $3.15M in Q3 2017. 639 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

  • AHL Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • AHL Partners sold 7,044 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $3.15M.
  • AHL Partners first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 7 quarters.
  • AHL Partners's Regeneron Pharmaceuticals position peaked at $3.15M in Q3 2017.
  • 639 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.